Skip to main content
. 2021 Apr 22;13:17588359211006950. doi: 10.1177/17588359211006950

Figure 1.

Figure 1.

Radar plot ranking the cancer immunity and response to immune checkpoint blockade therapy of lung adenocarcinomas with KRAS-only, KRAS/LKB1 or KRAS/TP53 mutational pattern into four degrees including negative (Neg), low (Lo), middle (Mid) and high (Hi).

ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1.